Tumor Biology

, Volume 36, Issue 10, pp 7755–7764 | Cite as

Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma—an in vivo and in vitro study

  • Lauri Jouhi
  • Neeta Datta
  • Suvi Renkonen
  • Timo Atula
  • Antti Mäkitie
  • Caj Haglund
  • Abdirisak Ahmed
  • Stina Syrjänen
  • Reidar Grénman
  • Eeva Auvinen
  • Sanna Lehtonen
  • Jaana Hagström
Research Article

Abstract

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased over the past decades in many western countries. This trend is mainly attributed to the human papillomavirus (HPV). Cancer-related actions of immunological defense systems are being intensively researched. Human toll-like receptors (TLRs) are a family of pattern recognition receptors that participate in the immunological defense against pathogens, but their actions are also linked to cancer. The expression of TLRs in cervical epithelium alters both during the clearance of HPV infection and the HPV-induced neoplasia, but the expression of TLRs has not been studied in OPSCC. Thirty-five paraffin-embedded, formalin-fixed, squamous cell carcinoma tissue specimens were analyzed for TLRs 2, 3, 4, 5, 7, and 9 and HPV and p16 statuses. The TLR 9 expression was lower in HPV-positive tumors compared with HPV-negative tumors. TLR 7 was expressed in all cancer specimens, but elevated expression was evident in HPV and/or p16-positive tumors. The majority of p16-positive tumors did not express TLR 5, whereas its expression was stronger in p16-negative tumors. The results of in vitro analysis of five human OPSCC cell lines and one human oral tongue squamous cell carcinoma cell line agree with the in vivo trends: low levels of TLR 5 and high levels of TLR 7 in p16-positive OPSCC. Overall, TLR 7 and 9 expression patterns are demonstrated here to relate to the HPV status in vivo and TLR 5 and 7 expression patterns to the p16 status in vivo and in vitro.

Keywords

Head and neck cancer Oropharynx Carcinoma HPV p16 Toll-like receptor 

Notes

Acknowledgments

We wish to thank Mrs. Elina Aspiala and Mrs. Päivi Peltokangas for technical assistance, and Prof. Tuula Salo for providing the tongue cancer cell line. We thank Orion Pharmos Foundation, the Research Foundation of Finnish Otolaryngological Association, the Academy of Finland (218021, 255551; SL), and the European Research Council (242820; SL) for funding.

Conflict of interest

None

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26:612–9.CrossRefGoogle Scholar
  2. 2.
    Braakhuis BJ, Visser O, Leemans CR. Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: increasing incidence, but not in young adults. Oral Oncol. 2009;45:e85–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Hakulinen T, Tryggvadottir L, Gislum M, Storm HH, Bray F, Klint A, et al. Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol. 2010;49:561–77.CrossRefPubMedGoogle Scholar
  4. 4.
    Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ramqvist T, Dalianis T. Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis. 2010;16:1671–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121:1813–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Chen AM, Li J, Beckett LA, Zhara T, Farwell G, Lau DH, et al. Differential response rates to irradiation among patients with human papillomavirus positive and negative oropharyngeal cancer. Laryngoscope. 2013;123:152–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Yu L, Wang L, Li M, Zhong J, Wang Z, Chen S. Expression of toll-like receptor 4 is down-regulated during progression of cervical neoplasia. Cancer Immunol Immunother. 2010;59:1021–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2009;388:621–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Kauppila JH, Mattila AE, Karttunen TJ, Salo T. Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer. 2013;108:638–43.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Helminen O, Huhta H, Takala H, Lehenkari PP, Saarnio J, Kauppila JH, et al. Increased Toll-like receptor 5 expression indicates esophageal columnar dysplasia. Virchows Arch. 2014;464:11–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Janeway Jr CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54:1–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Medzhitov R, Janeway Jr CA. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997;91:295–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol. 2005;17:338–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.CrossRefPubMedGoogle Scholar
  19. 19.
    Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of Toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35:1297–316.CrossRefPubMedGoogle Scholar
  21. 21.
    Ioannou S, Voulgarelis M. Toll-like receptors, tissue injury, and tumourigenesis. Mediat Inflamm. 2010;2010:581837.CrossRefGoogle Scholar
  22. 22.
    Daud II, Scott ME, Ma Y, Shiboski S, Farhat S, Moscicki AB. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer. 2011;128:879–86.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol. 2012;2012:785825.CrossRefPubMedGoogle Scholar
  24. 24.
    Cannella F, Pierangeli A, Scagnolari C, Cacciotti G, Tranquilli G, Stentella P, et al. TLR9 is expressed in human papillomavirus-positive cervical cells and is overexpressed in persistent infections. Immunobiology. 2015;220:363–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Allen CT, Lewis Jr JS, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope. 2010;120:1756–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010;116:2166–73.PubMedGoogle Scholar
  27. 27.
    Lewis Jr JS, Thorstad WL, Chernock RD, Haughey BH, Yip JH, Zhang Q, et al. p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol. 2010;34:1088–96.CrossRefPubMedGoogle Scholar
  28. 28.
    Ukpo OC, Flanagan JJ, Ma XJ, Luo Y, Thorstad WL, Lewis Jr JS. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol. 2011;35:1343–50.CrossRefPubMedGoogle Scholar
  29. 29.
    Reimers N, Kasper HU, Weissenborn SJ, Stutzer H, Preuss SF, Hoffmann TK, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007;120:1731–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Mellin Dahlstrand H, Lindquist D, Bjornestal L, Ohlsson A, Dalianis T, Munck-Wikland E, et al. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res. 2005;25:4375–83.PubMedGoogle Scholar
  31. 31.
    Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer. 2007;121:2465–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Klussmann JP, Gultekin E, Weissenborn SJ, Wieland U, Dries V, Dienes HP, et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol. 2003;162:747–53.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Schlecht NF, Brandwein-Gensler M, Nuovo GJ, Li M, Dunne A, Kawachi N, et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol. 2011;24:1295–305.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bussu F, Sali M, Gallus R, Vellone VG, Zannoni GF, Autorino R, et al. HPV infection in squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is p16 immunohistochemistry a reliable surrogate marker? Br J Cancer. 2013;108:1157–62.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol. 2006;44:504–12.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sugiyama M, Bhawal UK, Dohmen T, Ono S, Miyauchi M, Ishikawa T. Detection of human papillomavirus-16 and HPV-18 DNA in normal, dysplastic, and malignant oral epithelium. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95:594–600.CrossRefPubMedGoogle Scholar
  38. 38.
    Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, et al. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer. 2008;18:300–5.CrossRefPubMedGoogle Scholar
  39. 39.
    Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque Jr R, et al. Helicobacter pylori induces increased expression of Toll-like receptors and decreased Toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. Helicobacter. 2013;18:22–32.CrossRefPubMedGoogle Scholar
  40. 40.
    Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque Jr R, et al. Decreased Toll-interacting protein and peroxisome proliferator-activated receptor are associated with increased expression of Toll-like receptors in colon carcinogenesis. J Clin Pathol. 2012;65:302–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Park JH, Yoon HE, Kim DJ, Kim SA, Ahn SG, Yoon JH. Toll-like receptor 5 activation promotes migration and invasion of salivary gland adenocarcinoma. J Oral Pathol Med. 2011;40:187–93.CrossRefPubMedGoogle Scholar
  42. 42.
    Park JH, Yoon HE, Jeon DI, Ahn SG, Yoon JH. Activation of TLR2 and TLR5 did not affect tumor progression of an oral squamous cell carcinoma, YD-10B cells. J Oral Pathol Med. 2010;39:781–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011;71:2466–75.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320:226–30.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Sheyhidin I, Nabi G, Hasim A, Zhang RP, Ainiwaer J, Ma H, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011;17:3745–51.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Cherfils-Vicini J, Damotte D, Fridman WH, Sautes-Fridman C, Cremer I. Human lung cancer: role of TLR7 and TLR8 in cell survival and chemoresistance. M S-Med Sci. 2010;26:435–7.Google Scholar
  47. 47.
    Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest. 2010;120:1285–97.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Ahn MY, Kwon SM, Cheong HH, Park JH, Lee J, Min SK, et al. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med. 2012;41:540–6.PubMedGoogle Scholar
  49. 49.
    Jouhi L, Renkonen S, Atula T, Mäkitie A, Haglund C, Hagström J. Different toll-like receptor expression patterns in progression toward cancer. Front Immunol. 2014;5:638.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, et al. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol. 2010;185:6439–47.CrossRefPubMedGoogle Scholar
  51. 51.
    Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, et al. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One. 2011;6:e26315.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, et al. The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol. 2013;87:13009–19.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol. 2007;178:3186–97.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Lauri Jouhi
    • 1
  • Neeta Datta
    • 2
  • Suvi Renkonen
    • 1
  • Timo Atula
    • 1
  • Antti Mäkitie
    • 1
  • Caj Haglund
    • 3
  • Abdirisak Ahmed
    • 4
  • Stina Syrjänen
    • 5
  • Reidar Grénman
    • 6
  • Eeva Auvinen
    • 7
  • Sanna Lehtonen
    • 2
  • Jaana Hagström
    • 8
  1. 1.Department of Otorhinolaryngology—Head and Neck SurgeryUniversity of Helsinki and Helsinki University HospitalHelsinkiFinland
  2. 2.Department of PathologyUniversity of HelsinkiHelsinkiFinland
  3. 3.Department of SurgeryUniversity of Helsinki and Helsinki University HospitalHelsinkiFinland
  4. 4.Department of Oral and Maxillofacial DiseasesUniversity of HelsinkiHelsinkiFinland
  5. 5.Department of Oral Pathology, Institute of Dentistry, Faculty of Medicine and MediCity Research laboratoryUniversity of TurkuTurkuFinland
  6. 6.Department of Otorhinolaryngology—Head and Neck Surgery and Department of Medical BiochemistryTurku University Hospital, University of TurkuTurkuFinland
  7. 7.Department of VirologyUniversity of Helsinki and Helsinki University HospitalHelsinkiFinland
  8. 8.Department of Pathology and Oral PathologyUniversity of Helsinki and Helsinki University HospitalHelsinkiFinland

Personalised recommendations